Covid19
+1
The South African Coronavirus Disease of 2019 (COVID-19) Surgical Outcomes Study
Sponsored by Sefako Makgatho Health Sciences University
About this trial
Last updated 4 years ago
Study ID
SMUREC/M/184/2020
Status
Unknown status
Type
Observational
Placebo
No
Accepting
18+ Years
All
Not accepting
Healthy Volunteers
Trial Timing
Ended 2 years ago
What is this trial about?
The infectious coronavirus disease of 2019 (COVID-19), caused by corona virus SARS-severe
acute respiratory syndrome corona virus 2 (SARS-CoV-2) has caused significant disruption
in surgical services to patients globally. Data from the COVIDSurg Cohort Study suggest
mortality rates of patients infected with SARS-Cov-2 in the peri-operative period of up
to 25.6% in emergency surgery and 18.9% in elective surgery. Based on estimates by the
COVIDSurg Collaborative, large numbers of elective surgical procedures are cancelled. The
COVID-19 pandemic has forced healthcare providers to 'shift from patient-centred ethics
to public health ethics'. This has had impact on pre-operative testing for COVID-19, and
scheduling of surgery. Currently, a provisional recommendation to delay surgery for at
least four weeks after a positive COVID test, exists. Weighing the risk of surgery and
potential complications during the COVID-19 pandemic, against the benefit of undergoing a
surgical procedure to improve quality of life, remains difficult. A study to determine
the long term effect of the pandemic on patient-reported outcome may provide guidance on
how to safely return to surgical activity that are again more focused on individualized
care. There is also the opportunity to record outcomes that are currently accepted as the
standard for understanding longer term recovery after surgery.
What are the participation requirements?
Inclusion Criteria
- Adult patients presenting for any surgical procedure at South African hospitals during the specified study period.
Exclusion Criteria
- Patients unable to provide consent to participation.
- Patients whose legal guardian is unable to provide consent to participation (if applicable).
- Patients unable to nominate next-of-kin, guardian of or a person of their choice, as their representative during follow-up.